Martha Chung-Sang Man, MD
Hematology/Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: El Camino Health · Good Samaritan Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Man’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A82063 · Current
Licensed to practise in California · since 2003 · expires 2028-08-31 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$82,954
Medicare paid this office $82,954 for 422 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 251 | $39,338 | $80 |
| Long return visit (40+ min) | 63 | $15,646 | $127 |
| Short return visit (20+ min) | 128 | $7,771 | $50 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 285 | $6,681 | $15 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $4,741 | $105 |
See all 8 services
| Return visit (30+ min) | 251 | $39,338 | $80 |
| Long return visit (40+ min) | 63 | $15,646 | $127 |
| Short return visit (20+ min) | 128 | $7,771 | $50 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 285 | $6,681 | $15 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $4,741 | $105 |
| New patient visit (60+ min) | 23 | $3,494 | $152 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $2,594 | $70 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 19 | $788 | $26 |
Who their Medicare patients are
422 Original Medicare patients in 2024. Average age 76 · Women 90% · Also on Medicaid 10% · Health risk score 1.31. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: Cancer 75% · High blood pressure 72% · Diabetes 23% · Coronary heart disease 22% · Chronic kidney disease 21% · Atrial fibrillation 16% · Heart failure 15% · Depression 15% · COPD 10% · Stroke 8% · Dementia 6%.
The office billed $227,231, Medicare allowed $113,991 and paid $82,954; for 1,379 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 422 | 1,379 | 76 | 1.31 | $227,231 | $82,954 |
| 2023 | 416 | 1,010 | 76 | 1.38 | $212,416 | $86,206 |
| 2022 | 400 | 969 | 77 | 1.24 | $185,474 | $76,368 |
| 2021 | 426 | 1,023 | 77 | 1.29 | $201,021 | $83,447 |
| 2020 | 449 | 1,140 | 76 | 1.43 | $259,898 | $84,898 |
| 2019 | 493 | 1,267 | 76 | 1.29 | $196,023 | $88,244 |
| 2018 | 500 | 1,328 | 75 | 1.27 | $197,775 | $89,163 |
| 2017 | 510 | 1,146 | 75 | 1.33 | $174,312 | $68,001 |
| 2016 | 508 | 1,172 | 75 | 1.27 | $178,476 | $62,913 |
| 2015 | 529 | 22,706 | 75 | 1.38 | $1,669,626 | $395,019 |
| 2014 | 601 | 50,745 | 75 | 1.42 | $3,836,718 | $872,827 |
| 2013 | 616 | 32,472 | 75 | 1.42 | $3,047,033 | $843,870 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Return visit (30+ min) | 268 | $45,353 | $80 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 41 | $12,624 | $107 |
| Long return visit (40+ min) | 53 | $12,025 | $125 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $4,776 | $71 |
| Short return visit (20+ min) | 89 | $4,734 | $50 |
| New patient visit (60+ min) | 25 | $3,914 | $157 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 11 | $510 | $27 |
2022: 8 services
| Return visit (30+ min) | 246 | $40,329 | $81 |
| Long return visit (40+ min) | 45 | $13,357 | $125 |
| Short return visit (20+ min) | 171 | $9,856 | $45 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $4,929 | $93 |
| New patient visit (60+ min) | 20 | $2,802 | $140 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,810 | $65 |
| Extended inpatient or observation hospital service, first hour | 18 | $1,489 | $83 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 12 | $522 | $27 |
2021: 7 services
| Return visit (30+ min) | 265 | $44,047 | $81 |
| Long return visit (40+ min) | 48 | $11,917 | $124 |
| Short return visit (20+ min) | 153 | $9,265 | $50 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $9,131 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $2,902 | $67 |
| New patient visit (60+ min) | 14 | $2,450 | $175 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $2,082 | $189 |
2020: 10 services
| Return visit (30+ min) | 281 | $38,503 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 66 | $15,334 | $98 |
| Extended patient service without direct patient contact, first hour | 64 | $9,381 | $103 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 35 | $4,642 | $67 |
| Long return visit (40+ min) | 29 | $3,995 | $102 |
| New patient visit (60+ min) | 27 | $3,952 | $146 |
| Short return visit (20+ min) | 86 | $3,894 | $37 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,684 | $192 |
| Telephone medical discussion with physician, 11-20 minutes | 24 | $1,099 | $46 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $958 | $74 |
2019: 7 services
| Return visit (30+ min) | 329 | $47,679 | $65 |
| Extended patient service without direct patient contact, first hour | 88 | $12,282 | $100 |
| Short return visit (20+ min) | 175 | $8,083 | $37 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $6,697 | $94 |
| New patient visit (60+ min) | 41 | $6,027 | $147 |
| Long return visit (40+ min) | 35 | $4,280 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,254 | $66 |
2018: 8 services
| Return visit (30+ min) | 274 | $41,061 | $64 |
| Short return visit (20+ min) | 246 | $11,941 | $37 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $9,549 | $94 |
| Extended patient service without direct patient contact, first hour | 62 | $8,652 | $101 |
| New patient visit (60+ min) | 44 | $6,336 | $144 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $4,249 | $65 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,456 | $182 |
| Long return visit (40+ min) | 30 | $3,455 | $99 |
2017: 6 services
| Return visit (30+ min) | 230 | $33,687 | $67 |
| Short return visit (20+ min) | 320 | $16,543 | $37 |
| New patient visit (60+ min) | 45 | $6,198 | $138 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $4,998 | $91 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 33 | $3,757 | $65 |
| Long return visit (40+ min) | 13 | $1,295 | $100 |
2016: 7 services
| Short return visit (20+ min) | 403 | $28,377 | $39 |
| Return visit (30+ min) | 123 | $16,294 | $66 |
| New patient visit (60+ min) | 38 | $5,516 | $145 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 23 | $4,308 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $3,704 | $93 |
| Long return visit (40+ min) | 16 | $1,835 | $97 |
| Short return visit | 14 | $357 | $20 |
2015: 13 services
| Short return visit (20+ min) | 320 | $27,450 | $56 |
| Short return visit (20+ min) | 281 | $16,800 | $44 |
| Return visit (30+ min) | 68 | $9,989 | $88 |
| Administration of chemotherapy into vein, 1 hour or less | 13 | $8,219 | $137 |
| Return visit (30+ min) | 53 | $6,194 | $70 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $6,080 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 40 | $5,448 | $64 |
| New patient visit (60+ min) | 29 | $5,154 | $178 |
| New patient visit (60+ min) | 22 | $3,184 | $145 |
| Injection of drug or substance under skin or into muscle | 23 | $2,031 | $25 |
| Long return visit (40+ min) | 11 | $1,488 | $124 |
| Short return visit | 12 | $747 | $39 |
| Short return visit | 14 | $361 | $23 |
2014: 22 services
| Injection, denosumab, 1 mg | 14 | $66,011 | None |
| Short return visit (20+ min) | 467 | $61,953 | $62 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 25 | $59,946 | None |
| Administration of chemotherapy into vein, 1 hour or less | 26 | $24,483 | $136 |
| Return visit (30+ min) | 120 | $23,705 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 52 | $12,384 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 59 | $9,415 | $64 |
| Injection, palonosetron hcl, 25 mcg | 17 | $8,345 | None |
| New patient visit (60+ min) | 45 | $8,263 | $184 |
| Injection of drug or substance under skin or into muscle | 46 | $6,673 | $25 |
| Administration of additional new drug or substance into vein, 1 hour or less | 14 | $4,406 | $63 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 12 | $3,856 | $70 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 25 | $3,605 | $30 |
| Long return visit (40+ min) | 20 | $3,123 | $125 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $3,058 | $180 |
| Short return visit | 37 | $2,573 | $39 |
| Injection of additional new drug or substance into vein | 25 | $2,530 | $22 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 11 | $740 | $20 |
| Administration of influenza virus vaccine | 21 | $646 | $28 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 20 | $331 | $15 |
| Injection, dexamethasone sodium phosphate, 1 mg | 20 | $105 | None |
| Injection, ranitidine hydrochloride, 25 mg | 11 | $88 | None |
2013: 24 services
| Injection, pegfilgrastim, 6 mg | 11 | $90,788 | None |
| Injection, denosumab, 1 mg | 13 | $73,073 | None |
| Return visit (30+ min) | 274 | $52,718 | $89 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 27 | $33,028 | None |
| Short return visit (20+ min) | 351 | $32,598 | $64 |
| Administration of chemotherapy into vein, 1 hour or less | 26 | $23,587 | $147 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 75 | $18,660 | $90 |
| Injection, palonosetron hcl, 25 mcg | 22 | $16,055 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 69 | $13,578 | $62 |
| New patient visit (60+ min) | 71 | $12,492 | $176 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $7,151 | $174 |
| Injection of drug or substance under skin or into muscle | 50 | $6,537 | $25 |
| Administration of additional new drug or substance into vein, 1 hour or less | 14 | $4,143 | $73 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 22 | $4,084 | $32 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 13 | $3,609 | $74 |
| Long return visit (40+ min) | 24 | $3,326 | $133 |
| Injection of additional new drug or substance into vein | 24 | $2,316 | $23 |
| Short return visit | 16 | $1,171 | $42 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 13 | $694 | $18 |
| Administration of influenza virus vaccine | 22 | $607 | $28 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 20 | $288 | $14 |
| Injection, ranitidine hydrochloride, 25 mg | 14 | $89 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 17 | $78 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 15 | $17 | None |
Drugs they prescribed that Part D paid
$991,381
Pharmacies billed $991,381 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
227 generic and 65 brand-name prescriptions · $991,381 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Calquence | 13 | $139,124 | $10,702 |
| Anastrozole | 62 | $879 | $14 |
| Exemestane | 11 | $532 | $48 |
| Tamoxifen Citrate | 14 | $295 | $21 |
| Hydroxyurea | 13 | $233 | $18 |
Year by year
| 2024 | 292 | 90 | None | 22% | $991,381 |
| 2023 | 302 | 97 | 5% (16) | None | $618,381 |
| 2022 | 291 | 77 | 4% (11) | None | $519,910 |
| 2021 | 275 | 78 | 6% (15) | 21% | $572,727 |
| 2020 | 351 | 98 | 8% (29) | 19% | $618,119 |
| 2019 | 893 | 182 | 7% (62) | 18% | $1,038,609 |
| 2018 | 1,201 | 219 | 6% (77) | 14% | $1,110,218 |
| 2017 | 1,250 | 222 | 4% (51) | 14% | $1,244,465 |
| 2016 | 1,249 | 213 | 5% (56) | 16% | $1,102,759 |
| 2015 | 1,288 | 224 | 5% (68) | 15% | $703,995 |
| 2014 | 1,402 | 214 | 7% (93) | 15% | $616,386 |
| 2013 | 1,129 | 177 | 6% (72) | 11% | $252,220 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Calquence | 11 | $122,312 | $11,119 |
| Anastrozole | 45 | $862 | $19 |
| Hydrocodone-Acetaminophen | 11 | $223 | $20 |
| Tamoxifen Citrate | 13 | $200 | $15 |
| Prochlorperazine Maleate | 12 | $105 | $9 |
| Acyclovir | 19 | $105 | $6 |
| Ondansetron | 13 | $46 | $4 |
2022: 4 drugs
| Verzenio | 12 | $94,152 | $7,846 |
| Anastrozole | 59 | $986 | $17 |
| Gabapentin | 11 | $185 | $17 |
| Lorazepam | 12 | $72 | $6 |
2021: 5 drugs
| Revlimid | 20 | $373,988 | $18,699 |
| Eliquis | 11 | $5,728 | $521 |
| Anastrozole | 54 | $1,314 | $24 |
| Tamoxifen Citrate | 15 | $530 | $35 |
| Gabapentin | 14 | $340 | $24 |
2020: 6 drugs
| Revlimid | 22 | $353,603 | $16,073 |
| Anastrozole | 91 | $2,383 | $26 |
| Tamoxifen Citrate | 16 | $625 | $39 |
| Dexamethasone | 14 | $459 | $33 |
| Hydrocodone-Acetaminophen | 11 | $175 | $16 |
| Ondansetron | 14 | $153 | $11 |
2019: 18 drugs
| Revlimid | 18 | $288,509 | $16,028 |
| Ibrance | 21 | $250,068 | $11,908 |
| Exemestane | 38 | $12,014 | $316 |
| Anastrozole | 270 | $6,729 | $25 |
| Tamoxifen Citrate | 27 | $1,293 | $48 |
| Letrozole | 39 | $995 | $26 |
| Hydroxyurea | 14 | $647 | $46 |
| Gabapentin | 38 | $531 | $14 |
| Potassium Chloride | 17 | $447 | $26 |
| Dexamethasone | 12 | $341 | $28 |
| Alendronate | 19 | $220 | $12 |
| Acyclovir | 12 | $212 | $18 |
| Hydrocodone-Acetaminophen | 16 | $202 | $13 |
| Ondansetron | 16 | $173 | $11 |
| Lorazepam | 18 | $169 | $9 |
| Venlafaxine Hcl Er | 14 | $135 | $10 |
| Prochlorperazine Maleate | 12 | $132 | $11 |
| Escitalopram | 11 | $112 | $10 |
2018: 27 drugs
| Ibrance | 45 | $521,615 | $11,591 |
| Revlimid | 11 | $201,132 | $18,285 |
| Xtandi | 12 | $95,110 | $7,926 |
| Exemestane | 46 | $29,395 | $639 |
| Arimidex | 11 | $7,741 | $704 |
| Anastrozole | 363 | $6,978 | $19 |
| Xarelto | 11 | $4,716 | $429 |
| Enoxaparin | 15 | $3,314 | $221 |
| Tamoxifen Citrate | 35 | $1,806 | $52 |
| Letrozole | 55 | $1,206 | $22 |
| Hydroxyurea | 23 | $1,000 | $43 |
| Oxycodone-Acetaminophen | 19 | $841 | $44 |
| Potassium Chloride | 14 | $617 | $44 |
| Gabapentin | 53 | $582 | $11 |
| Hydrocodone-Acetaminophen | 26 | $578 | $22 |
| Dexamethasone | 24 | $490 | $20 |
| Venlafaxine Hcl Er | 22 | $453 | $21 |
| Alendronate | 40 | $328 | $8 |
| Acyclovir | 16 | $286 | $18 |
| Ondansetron | 19 | $247 | $13 |
| Warfarin | 11 | $211 | $19 |
| Lorazepam | 30 | $196 | $7 |
| Levofloxacin | 14 | $138 | $10 |
| Prochlorperazine Maleate | 18 | $124 | $7 |
| Ranitidine | 11 | $118 | $11 |
| Prednisone | 12 | $93 | $8 |
| Hydrochlorothiazide | 13 | $14 | $1 |
2017: 25 drugs
| Ibrance | 49 | $556,105 | $11,349 |
| Afinitor | 13 | $180,096 | $13,854 |
| Revlimid | 15 | $178,718 | $11,915 |
| Xtandi | 12 | $89,271 | $7,439 |
| Exemestane | 58 | $40,268 | $694 |
| Arimidex | 15 | $7,101 | $473 |
| Anastrozole | 385 | $6,765 | $18 |
| Letrozole | 85 | $5,055 | $59 |
| Tamoxifen Citrate | 84 | $3,460 | $41 |
| Hydroxyurea | 26 | $1,268 | $49 |
| Potassium Chloride | 15 | $1,105 | $74 |
| Hydrocodone-Acetaminophen | 26 | $642 | $25 |
| Acyclovir | 20 | $389 | $19 |
| Gabapentin | 28 | $382 | $14 |
| Venlafaxine Hcl Er | 14 | $369 | $26 |
| Warfarin | 21 | $351 | $17 |
| Levothyroxine | 12 | $336 | $28 |
| Dexamethasone | 21 | $257 | $12 |
| Lorazepam | 36 | $212 | $6 |
| Zolpidem | 25 | $200 | $8 |
| Alendronate | 17 | $177 | $10 |
| Prochlorperazine Maleate | 20 | $128 | $6 |
| Ondansetron | 15 | $114 | $8 |
| Prednisone | 13 | $63 | $5 |
| Hydrochlorothiazide | 12 | $10 | $1 |
2016: 25 drugs
| Ibrance | 54 | $560,247 | $10,375 |
| Revlimid | 16 | $183,266 | $11,454 |
| Xtandi | 13 | $96,904 | $7,454 |
| Tarceva | 11 | $76,800 | $6,982 |
| Exemestane | 77 | $28,724 | $373 |
| Anastrozole | 396 | $6,662 | $17 |
| Arimidex | 12 | $5,752 | $479 |
| Tamoxifen Citrate | 93 | $2,098 | $23 |
| Letrozole | 94 | $1,311 | $14 |
| Hydrocodone-Acetaminophen | 31 | $882 | $28 |
| Valsartan | 12 | $857 | $71 |
| Zolpidem | 27 | $492 | $18 |
| Levothyroxine | 11 | $445 | $40 |
| Potassium Chloride | 17 | $428 | $25 |
| Warfarin | 21 | $303 | $14 |
| Venlafaxine Hcl Er | 13 | $253 | $19 |
| Gabapentin | 23 | $241 | $10 |
| Dexamethasone | 11 | $238 | $22 |
| Lorazepam | 29 | $204 | $7 |
| Ondansetron | 12 | $123 | $10 |
| Methadone | 12 | $105 | $9 |
| Prednisone | 14 | $103 | $7 |
| Omeprazole | 16 | $97 | $6 |
| Alendronate | 14 | $83 | $6 |
| Prochlorperazine Maleate | 11 | $62 | $6 |
2015: 21 drugs
| Ibrance | 22 | $218,565 | $9,935 |
| Revlimid | 12 | $121,492 | $10,124 |
| Tarceva | 14 | $72,327 | $5,166 |
| Exemestane | 124 | $44,246 | $357 |
| Enoxaparin | 20 | $13,803 | $690 |
| Anastrozole | 399 | $6,489 | $16 |
| Xarelto | 13 | $4,209 | $324 |
| Tamoxifen Citrate | 137 | $3,658 | $27 |
| Hydrocodone-Acetaminophen | 40 | $1,130 | $28 |
| Hydroxyurea | 17 | $730 | $43 |
| Letrozole | 69 | $609 | $9 |
| Levothyroxine | 11 | $480 | $44 |
| Zolpidem | 30 | $462 | $15 |
| Venlafaxine Hcl Er | 24 | $431 | $18 |
| Gabapentin | 31 | $304 | $10 |
| Omeprazole | 17 | $117 | $7 |
| Alendronate | 19 | $113 | $6 |
| Prednisone | 12 | $108 | $9 |
| Dexamethasone | 11 | $92 | $8 |
| Lorazepam | 17 | $84 | $5 |
| Prochlorperazine Maleate | 13 | $66 | $5 |
2014: 24 drugs
| Zytiga | 12 | $138,137 | $11,511 |
| Revlimid | 15 | $127,046 | $8,470 |
| Tarceva | 19 | $103,685 | $5,457 |
| Tykerb | 11 | $46,023 | $4,184 |
| Exemestane | 127 | $35,731 | $281 |
| Anastrozole | 432 | $10,940 | $25 |
| Arimidex | 13 | $5,754 | $443 |
| Tamoxifen Citrate | 191 | $4,470 | $23 |
| Vagifem | 13 | $2,148 | $165 |
| Hydrocodone-Acetaminophen | 50 | $1,128 | $23 |
| Oxycodone-Acetaminophen | 14 | $691 | $49 |
| Venlafaxine Hcl Er | 23 | $546 | $24 |
| Letrozole | 25 | $495 | $20 |
| Levothyroxine | 14 | $323 | $23 |
| Zolpidem | 39 | $286 | $7 |
| Dexamethasone | 27 | $254 | $9 |
| Alendronate | 26 | $249 | $10 |
| Warfarin | 19 | $241 | $13 |
| Gabapentin | 29 | $211 | $7 |
| Prednisone | 16 | $187 | $12 |
| Acyclovir | 13 | $164 | $13 |
| Ondansetron | 11 | $143 | $13 |
| Prochlorperazine Maleate | 13 | $84 | $6 |
| Lorazepam | 14 | $76 | $5 |
2013: 18 drugs
| Exemestane | 94 | $25,523 | $272 |
| Anastrozole | 334 | $12,178 | $36 |
| Arimidex | 12 | $5,333 | $444 |
| Fentanyl | 18 | $2,879 | $160 |
| Tamoxifen Citrate | 154 | $2,572 | $17 |
| Letrozole | 41 | $2,243 | $55 |
| Megestrol Acetate | 13 | $791 | $61 |
| Acyclovir | 17 | $546 | $32 |
| Gabapentin | 28 | $531 | $19 |
| Hydrocodone-Acetaminophen | 31 | $477 | $15 |
| Alendronate | 46 | $451 | $10 |
| Zolpidem | 32 | $222 | $7 |
| Venlafaxine Hcl Er | 13 | $209 | $16 |
| Dexamethasone | 11 | $157 | $14 |
| Levothyroxine | 12 | $128 | $11 |
| Prochlorperazine Maleate | 21 | $127 | $6 |
| Lorazepam | 22 | $97 | $4 |
| Prednisone | 17 | $89 | $5 |
Money from drug and device companies
$29 in 2025
| 2025 | 1 | 1 | None | $29 |
| 2023 | 1 | 1 | None | $20 |
| 2021 | 2 | 5 | None | $64 |
| 2020 | 1 | 1 | None | $14 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Gilead Sciences | Trodelvy | $29 | 1 payment
|
See the published payment
| Gilead Sciences | Meals · 2025-10-21 | Trodelvy | $29 |
See earlier years (2023, 2021, 2020)
2023: $20
| Gilead Sciences | None | $20 | 1 payment
|
2021: $64
| Acrotech Biopharma | Beleodaq | $52 | 4 payments
|
| Gilead Sciences | None | $12 | 1 payment
|
2020: $14
| Pfizer | Xtandi | $14 | 1 payment
|
Professional record
- NPI
- 1518976042
- Licence
- CA A82063California A82063: Current · expires 2028-08-31
- Trained
- Stanford University School of Medicine, 2000
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A820630
- Taxonomy
- Medical oncology (207RX0202X); Internal medicine (207R00000X); Federal specialty code 207RH0000X (207RH0000X); Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 2589 Samaritan Dr, San Jose, CA, 95124
- NPI first listed
- 2006-08-05
- NPI last updated
- 2024-04-12
- NPI record certified
- 2024-04-12
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 50 E Hamilton Ave, Campbell, CA, 95008